Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 2/20 | 0.82 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimantadine SCHEMBL20409367 | 0.91 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL15532385 | 0.91 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL2982 | 0.91 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL29908943 | 0.91 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL2981 | 0.91 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| SCHEMBL13990979 | 0.88 | SLC22A2 (0.62) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL4366035 | 0.88 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL40906 | 0.88 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL28108817 | 0.88 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL14973619 | 0.86 | SLC22A2 (0.90) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008130550-A1 | DIAMONDOID DERIVATIVES POSSESSING THERAPEUTIC ACTIVITY IN THE TREATMENT OF NEUROLOGIC DISORDERS | CHEVRON U.S.A, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1982970-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | Chevron USA, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080009546-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | CHEVRON U.S.A. INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009546-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | CLN6, NLN, CDR2 | SLC22A2 2679/4885SLC47A1 1130/4885MAPT 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.